Where Will Titan Pharmaceuticals, Inc. common stock (TTNP) Stock Go Next After It Is Down 3.51% in a Week?

Friday, December 31, 2021 10:02 AM | InvestorsObserver Analysts

Mentioned in this article

Where Will Titan Pharmaceuticals, Inc. common stock (TTNP) Stock Go Next After It Is Down 3.51% in a Week?

Titan Pharmaceuticals, Inc. common stock (TTNP) stock is lower by 3.51% over the past week and gets a Neutral rating from InvestorsObserver Sentiment Indicator.

Titan Pharmaceuticals, Inc. common stock has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on TTNP!

See Full TTNP Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With TTNP Stock Today?

Titan Pharmaceuticals, Inc. common stock (TTNP) stock is trading at $1.10 as of 10:00 AM on Friday, Dec 31, an increase of $0.04, or 3.77% from the previous closing price of $1.06. The stock has traded between $1.10 and $1.16 so far today. Volume today is below average. So far 94,246 shares have traded compared to average volume of 476,003 shares.

More About Titan Pharmaceuticals, Inc. common stock

Titan Pharmaceuticals Inc is a pharmaceutical company developing therapeutics utilizing its proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases for which steady state delivery of a drug provides an efficacy and/or safety benefit. ProNeura consists of a small, solid implant made from a mixture of ethylene-vinyl acetate, or EVA, and a drug substance. Its first product based on ProNeura technology was Probuphine (buprenorphine) implant, which was approved in the United States, Canada and the European Union, for the maintenance treatment of opioid use disorder in clinically stable patients taking 8 mg or less a day of oral buprenorphine. Click Here to get the full Stock Report for Titan Pharmaceuticals, Inc. common stock stock.